Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.40 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7051028 | 0.99 | POLB (0.42) | POLBEPHX2HPGDGAAAGTR1 | |
| SCHEMBL7049824 | 0.83 | HPGD (0.36) | HPGDGAAAGTR1AGTR2ALDH1A1 | |
| SCHEMBL7049851 | 0.82 | AKR1C2 (0.38) | POLBHPGDGAAALDH1A1MAPT | |
| SCHEMBL7052307 | 0.78 | ALDH1A1 (0.33) | HPGDAGTR1AGTR2ALDH1A1MAPT | |
| SCHEMBL8997324 | 0.75 | SOAT1 (0.58) | POLBEPHX2AGTR1AGTR2 | |
| SCHEMBL7048488 | 0.69 | SOAT1 (0.41) | POLBEPHX2AGTR1AGTR2 | |
| SCHEMBL2807342 | 0.69 | EPHX2 (0.69) | EPHX2HPGDGAAALDH1A1 | |
| SCHEMBL7051023 | 0.69 | SOAT1 (0.43) | POLBEPHX2AGTR1AGTR2 | |
| SCHEMBL7048492 | 0.66 | PTGES (0.50) | POLBEPHX2 | |
| Stearylsulfamide SCHEMBL9219328 | 0.66 | EPHX2 (0.57) | POLBEPHX2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030191323-A1 | Hypoglycemic agent | AJINOMOTO CO., INC. (JP) | 2003-10-09 | — | — | US | disclosed |
| US-20030162818-A1 | Acylsulfonamide derivative | AJINOMOTO CO. INC. (JP) | 2003-08-28 | — | — | US | disclosed |
| US-6555584-B1 | Acetyl-coa carboxylase inhibitors | AJINOMOTO CO., INC. (JP) | 2003-04-29 | — | — | US | disclosed |
| EP-1300142-A1 | HYPOGLYCEMICS | Ajinomoto Co., Inc. (JP) | 2003-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162818-A1 | Acylsulfonamide derivative | ACSS2, ACACA, FASN | POLB 3359/4885EPHX2 1972/4885HPGD 3434/4885 |
| US-20030191323-A1 | Hypoglycemic agent | GPR119, IAPP, SLC5A2 | POLB 4682/4885EPHX2 3723/4885HPGD 1451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.